Immunoreactivity for GFAP is commonly used for labeling the intermediate filaments expressed in the cytoskeleton of astrocytes, and astrocytes with high levels of GFAP gene expression have been defined as ‘disease-associated astrocytes’ in AD rodent model. Here, GFAP is linked to Alzheimer disease.